Page last updated: 2024-10-16

adenine and Pneumonia, Pneumocystis

adenine has been researched along with Pneumonia, Pneumocystis in 4 studies

Pneumonia, Pneumocystis: A pulmonary disease in humans occurring in immunodeficient or malnourished patients or infants, characterized by DYSPNEA, tachypnea, and HYPOXEMIA. Pneumocystis pneumonia is a frequently seen opportunistic infection in AIDS. It is caused by the fungus PNEUMOCYSTIS JIROVECII. The disease is also found in other MAMMALS where it is caused by related species of Pneumocystis.

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lee, R1
Nayernama, A1
Jones, SC1
Wroblewski, T1
Waldron, PE1
Cheng, MP1
Kusztos, AE1
Gustine, JN1
Dryden-Peterson, SL1
Dubeau, TE1
Woolley, AE1
Hammond, SP1
Baden, LR1
Treon, SP1
Castillo, JJ1
Issa, NC1
Ahn, IE1
Jerussi, T1
Farooqui, M1
Tian, X1
Wiestner, A1
Gea-Banacloche, J1
Romero, E1
Hernández, JM1
Jarilla, F1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)[NCT02514083]Phase 229 participants (Actual)Interventional2015-12-09Active, not recruiting
A Phase II Study of PCI-32765 for Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Need Therapy and Are Older Than 65 or Have a 17p Deletion[NCT01500733]Phase 286 participants (Actual)Interventional2012-01-05Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Overall Response Rate at 6 Months

"The primary endpoint was response after 6 cycles of therapy. Overall response rate was calculated as complete response plus partial response, based on the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2008 criteria.as follows:~Complete response (CR): all group A and group B criteria are met~Group A criteria: resolution of enlarged lymph nodes, normal size spleen and liver, absolute lymphocyte count < 4,000/uL, normocellular bone marrow with < 30% lymphocytes without nodules~Group B criteria: improved blood count (platelet count > 100,000/uL, hemoglobin > 11.0 g/dL, neutrophils > 1,500/uL)~Partial response (PR): at least 2 of the group A criteria plus one of the group B criteria are met~Group A criteria: >=50% decrease in target lymph nodes, >=50% decrease in spleen size, >=50% decrease in liver size, 50% reduction in marrow infiltrates~Group B criteria: platelet count > 100,000/uL, hemoglobin > 11.0 g/dL, neutrophils > 1,500/uL" (NCT01500733)
Timeframe: 6 months

Interventionpercentage of participants (Number)
Elderly Cohort93.9
TP53 Cohort95.8

Trials

1 trial available for adenine and Pneumonia, Pneumocystis

ArticleYear
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.
    Blood, 2016, 10-13, Volume: 128, Issue:15

    Topics: Adenine; Aged; Follow-Up Studies; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; P

2016
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.
    Blood, 2016, 10-13, Volume: 128, Issue:15

    Topics: Adenine; Aged; Follow-Up Studies; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; P

2016
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.
    Blood, 2016, 10-13, Volume: 128, Issue:15

    Topics: Adenine; Aged; Follow-Up Studies; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; P

2016
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.
    Blood, 2016, 10-13, Volume: 128, Issue:15

    Topics: Adenine; Aged; Follow-Up Studies; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; P

2016

Other Studies

3 other studies available for adenine and Pneumonia, Pneumocystis

ArticleYear
Ibrutinib-associated Pneumocystis jirovecii pneumonia.
    American journal of hematology, 2017, Volume: 92, Issue:11

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Piperidines; Pneumocysti

2017
Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib.
    British journal of haematology, 2019, Volume: 185, Issue:4

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Invasive Fungal Infe

2019
[Renal tuberculosis and human immunodeficiency virus infection].
    Enfermedades infecciosas y microbiologia clinica, 2009, Volume: 27, Issue:6

    Topics: Acute Kidney Injury; Adenine; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral

2009